ABSTRACT
BACKGROUND: Antibodies against the human neutrophil alloantigen-3a (HNA-3a) are involved in severe cases of transfusion-related acute lung injury (TRALI), but the susceptibility of patients towards HNA-3a antibody differs largely. HNA-3a antibodies induce granulocyte aggregation. However, it is unresolved whether plasma proteins are required for granulocyte aggregation. MATERIALS AND METHODS: We investigated whether HNA-3a-antibody-induced aggregation of polymorphonuclear cells is dependent on plasma factors by using and modifying the granulocyte agglutination test (GAT). RESULTS: Polymorphonuclear cells homozygous for HNA-3a did not aggregate when incubated with HNA-3a antibodies in a plasma-protein-free GAT setup. When the GAT was performed using polymorphonuclear cells re-suspended in phosphate-buffered saline containing proteins, HNA-3-mediated aggregation was observed. Moreover, using Tween® 20 for blocking the plates, reconstituted the granulocyte aggregation in a protein-free medium. This indicates that granulocyte aggregation probably occurs by direct granulocyte-granulocyte interaction(s) or is mediated by substances released by neutrophils after activation. DISCUSSION: Granulocyte aggregation induced by HNA-3a antibodies does not require human plasma proteins. Interindividual variability in the response to HNA-3a antibodies does not depend on differences in patient's plasma proteins.
Subject(s)
Autoantibodies , Isoantigens/immunology , Neutrophils/immunology , Acute Lung Injury/etiology , Acute Lung Injury/immunology , Agglutination/drug effects , Agglutination/immunology , Autoantibodies/immunology , Autoantibodies/isolation & purification , Autoantibodies/pharmacology , Culture Media, Serum-Free , Female , Humans , Male , Transfusion ReactionABSTRACT
The tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-induced thrombocytopenia, a prothrombotic adverse drug reaction caused by immunoglobulin G directed against PF4/polyanion complexes. This study demonstrates that nucleic acids, including aptamers, also bind to PF4 and enhance PF4 binding to platelets. Systematic assessment of RNA and DNA constructs, as well as 4 aptamers of different lengths and secondary structures, revealed that increasing length and double-stranded segments of nucleic acids augment complex formation with PF4, while single nucleotides or single-stranded polyA or polyC constructs do not. Aptamers were shown by circular dichroism spectroscopy to induce structural changes in PF4 that resemble those induced by heparin. Moreover, heparin-induced anti-human-PF4/heparin antibodies cross-reacted with human PF4/nucleic acid and PF4/aptamer complexes, as shown by an enzyme immunoassay and a functional platelet activation assay. Finally, administration of PF4/44mer-DNA protein C aptamer complexes in mice induced anti-PF4/aptamer antibodies, which cross-reacted with murine PF4/heparin complexes. These data indicate that the formation of anti-PF4/heparin antibodies in postoperative patients may be augmented by PF4/nucleic acid complexes. Moreover, administration of therapeutic aptamers has the potential to induce anti-PF4/polyanion antibodies and a prothrombotic diathesis.
Subject(s)
Aptamers, Nucleotide/metabolism , Nucleic Acids/metabolism , Platelet Factor 4/immunology , Platelet Factor 4/metabolism , Animals , Antibodies/immunology , Antibodies/metabolism , Aptamers, Nucleotide/chemistry , Base Pairing , Base Sequence , Blood Platelets/metabolism , DNA/chemistry , DNA/metabolism , Heparin/pharmacology , Humans , Macromolecular Substances/metabolism , Mice , Molecular Sequence Data , Nucleic Acid Conformation , Nucleic Acids/chemistry , Platelet Activation/immunology , Polyelectrolytes , Polymers , Protein Binding/drug effects , RNA/chemistry , RNA/metabolismABSTRACT
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating immunoglobulin (Ig) G antibodies that recognize multimolecular complexes of platelet factor 4 (PF4) bound to heparin or other polyanions. Most laboratory assays for HIT have a high sensitivity for anti-PF4/heparin antibodies and a negative test generally excludes HIT (high negative predictive value), especially in a setting of a low pretest probability. The magnitude of a positive test result correlates with greater likelihood of HIT. Therefore, a combined diagnostic approach that considers the clinical picture and the magnitude of a positive test result is recommended for accurate diagnosis of HIT.
Subject(s)
Anticoagulants/adverse effects , Heparin/adverse effects , Thrombocytopenia/diagnosis , Anticoagulants/immunology , Anticoagulants/metabolism , Blood Coagulation , Enzyme-Linked Immunosorbent Assay , Heparin/immunology , Heparin/metabolism , Humans , Immunoglobulin G/immunology , Platelet Activation/immunology , Platelet Factor 4/immunology , Platelet Factor 4/metabolism , Thrombocytopenia/chemically induced , Thrombocytopenia/immunologyABSTRACT
Platelets play a dominant role in the pathogenesis of bleeding disorders and cardiovascular pathology (e.g., myocardial infarction). Nonradioactive labeling of platelets may offer several clinical applications, ranging from survival studies of transfused platelet concentrates to studies on the pathogenesis of stroke. We used ferucarbotran superparamagnetic nanoparticles (NPs) for cell labeling. Platelets incorporated these NPs by endocytosis (without linkers or binding agents). Flow cytometry using FITC-conjugated magnetic NPs showed ex vivo labeling of about 98% of platelets; NPs were predominantly located inside the platelet granules as confirmed by fluorescence microscopy and transmission electron microscopy. Iron concentrations of 2 pg per platelet were reached as determined by atomic absorption spectroscopy. This will enable sensitive ex vivo determination of transfused labeled platelets, allowing survival studies. In vitro, labeled platelets gave a clear signal by 7 Tesla magnetic resonance tomography. Magnetic labeling of platelets may offer a new tool for diagnosis and research in transfusion medicine and cardiovascular medicine. FROM THE CLINICAL EDITOR: In this study a platelet labeling method is discussed and described for in vivo and ex vivo applications, using a binder or linker free fluorescent superparamagnetic iron nanoparticle system. Magnetic labeling of platelets may offer a new tool for diagnosis and research in transfusion medicine and cardiovascular medicine.
Subject(s)
Blood Platelets/chemistry , Cell Tracking/methods , Dextrans/chemistry , Magnetite Nanoparticles/chemistry , Endocytosis , Ferric Compounds/chemistry , Humans , Magnetic Resonance Imaging , Staining and LabelingABSTRACT
Heparin is a widely used anticoagulant. Because of its negative charge, it forms complexes with positively charged platelet factor 4 (PF4). This can induce anti-PF4/heparin IgG Abs. Resulting immune complexes activate platelets, leading to the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT). HIT requires treatment with alternative anticoagulants. Approved for HIT are 2 direct thrombin inhibitors (DTI; lepirudin, argatroban) and danaparoid. They are niche products with limitations. We assessed the effects of the DTI dabigatran, the direct factor Xa-inhibitor rivaroxaban, and of 2-O, 3-O desulfated heparin (ODSH; a partially desulfated heparin with minimal anticoagulant effects) on PF4/heparin complexes and the interaction of anti-PF4/heparin Abs with platelets. Neither dabigatran nor rivaroxaban had any effect on the interaction of PF4 or anti-PF4/heparin Abs with platelets. In contrast, ODSH inhibited PF4 binding to gel-filtered platelets, displaced PF4 from a PF4-transfected cell line, displaced PF4/heparin complexes from platelet surfaces, and inhibited anti-PF4/heparin Ab binding to PF4/heparin complexes and subsequent platelet activation. Dabigatran and rivaroxaban seem to be options for alternative anticoagulation in patients with a history of HIT. ODSH prevents formation of immunogenic PF4/heparin complexes, and, when given together with heparin, may have the potential to reduce the risk for HIT during treatment with heparin.
Subject(s)
Antibodies/pharmacology , Benzimidazoles/pharmacology , Heparin/adverse effects , Heparin/pharmacology , Morpholines/pharmacology , Platelet Factor 4/pharmacology , Thiophenes/pharmacology , Thrombocytopenia/chemically induced , beta-Alanine/analogs & derivatives , Anticoagulants/adverse effects , Blood Cells/drug effects , Blood Cells/metabolism , Cells, Cultured , Dabigatran , Drug Evaluation, Preclinical , Drug Interactions , HEK293 Cells , Heparin/chemistry , Heparin/immunology , Humans , Platelet Factor 4/genetics , Platelet Factor 4/immunology , Platelet Factor 4/metabolism , Rivaroxaban , Sulfates/chemistry , Sulfates/pharmacology , Transfection , beta-Alanine/pharmacologyABSTRACT
BACKGROUND: Severe transfusion-related acute lung injury is often caused by antibodies directed against the human neutrophil alloantigen (HNA)-3a. HNA-3a results from an amino acid exchange (Arg154Gln) in the first extracellular loop of the choline transporter-like protein 2 (CTL2). The characteristics of the binding domain(s) of HNA-3a antibodies are unknown. STUDY DESIGN AND METHODS: For epitope mapping, a library of 23 different HNA-3a (R(154)) and three HNA-3b (Q(154)) peptides covering different parts of the first extracellular loop of CTL2 (aa(55-231)) was synthesized in Escherichia coli and tested by Western blot with two HNA-3a alloantibody-containing plasma samples and by enzyme immunoassay (EIA) with different HNA-3a- (n = 21) and HNA-3b- (n = 1) positive plasma samples. RESULTS: Despite promising Western blot results using highly reactive plasma samples, we found widely varying reactivities of different HNA-3a plasmas in the EIA, with only 11 of 21 HNA-3a antibodies binding to any of the tested HNA-3a peptides and with no peptide recognized by more than nine of the 21 antibodies. The HNA-3b plasma did not react with R(154) peptides in the EIA nor with R(154) or Q(154) peptides in Western blot experiments. Plasma reactivity profiles with the peptides did not correlate with those observed using granulocyte agglutination and granulocyte immunofluorescence tests. CONCLUSION: Binding of HNA-3a alloantibodies depends on the conformation of the intact CTL2 protein and their binding sites may differ substantially. Peptide-based assays for detection of HNA-3a antibodies bear the risk to be insensitive and require systematic validation with a large panel of antibodies.
Subject(s)
Epitope Mapping , Isoantibodies/immunology , Isoantigens/immunology , Plasma/immunology , Blood Transfusion , Blotting, Western , Female , Humans , Immunoenzyme Techniques , Isoantibodies/chemistry , Isoantigens/chemistry , Membrane Glycoproteins/chemistry , Membrane Transport Proteins/chemistry , Middle AgedABSTRACT
A clinically important adverse drug reaction, heparin-induced thrombocytopenia (HIT), is induced by antibodies specific for complexes of the chemokine platelet factor 4 (PF4) and the polyanion heparin. Even heparin-naive patients can generate anti-PF4/heparin IgG as early as day 4 of heparin treatment, suggesting preimmunization by antigens mimicking PF4/heparin complexes. These antibodies probably result from bacterial infections, as (1) PF4 bound charge-dependently to various bacteria, (2) human heparin-induced anti-PF4/heparin antibodies cross-reacted with PF4-coated Staphylococcus aureus and Escherichia coli, and (3) mice developed anti-PF4/heparin antibodies during polymicrobial sepsis without heparin application. Thus, after binding to bacteria, the endogenous protein PF4 induces antibodies with specificity for PF4/polyanion complexes. These can target a large variety of PF4-coated bacteria and enhance bacterial phagocytosis in vitro. The same antigenic epitopes are expressed when pharmacologic heparin binds to platelets augmenting formation of PF4 complexes. Boosting of preformed B cells by PF4/heparin complexes could explain the early occurrence of IgG antibodies in HIT. We also found a continuous, rather than dichotomous, distribution of anti-PF4/heparin IgM and IgG serum concentrations in a cross-sectional population study (n = 4029), indicating frequent preimmunization to modified PF4. PF4 may have a role in bacterial defense, and HIT is probably a misdirected antibacterial host defense mechanism.
Subject(s)
Antibodies/metabolism , Bacteria/immunology , Heparin , Platelet Factor 4/metabolism , Thrombocytopenia/chemically induced , Thrombocytopenia/immunology , Animals , Bacteria/metabolism , Bacterial Adhesion , Cross Reactions/immunology , Enzyme-Linked Immunosorbent Assay , Escherichia coli/immunology , Escherichia coli/metabolism , Female , Humans , Immunodominant Epitopes/immunology , Listeria monocytogenes/immunology , Listeria monocytogenes/metabolism , Mice , Mice, Inbred C57BL , Neisseria meningitidis/immunology , Neisseria meningitidis/metabolism , Protein Binding , Staphylococcus aureus/immunology , Staphylococcus aureus/metabolism , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/metabolism , Thrombocytopenia/metabolismABSTRACT
BACKGROUND: Bernard-Soulier syndrome (BSS) is a severe congenital bleeding disorder characterized by thrombocytopenia, thrombocytopathy and decreased platelet adhesion. BSS results from genetic alterations of the glycoprotein (GP) Ib/IX/V complex. METHODS: We report on a patient demonstrating typical BSS phenotype (thrombocytopenia with giant platelets, bleeding symptoms). However, BSS was not diagnosed until he reached the age of 39 years. RESULTS: Flow cytometry of the patient's platelets revealed absence of GPIb/IX/V receptor surface expression. In addition, immunofluorescence analysis of patient's platelets demonstrated very faint staining of GPIX. A novel homozygous deletion comprising 11 nucleotides starting at position 1644 of the GPIX gene was identified using molecular genetic analysis. CONCLUSIONS: The novel 11-nucleotide deletion (g.1644_1654del11) was identified as causing the bleeding disorder in the BSS patient. This homozygous deletion includes the last 4 nucleotides of the Kozak sequence as well as the start codon and the following 4 nucleotides of the coding sequence. The Kozak sequence is a region indispensable for the initiation of the protein translation process, thus preventing synthesis of functional GPIX protein in the case of deletion.
ABSTRACT
Transfusion-related acute lung injury (TRALI) is a frequent cause of transfusion-associated morbidity and mortality. Severe TRALI is often due to antibodies in blood components directed against the human neutrophil alloantigen-3a (HNA-3a). We show here that the HNA-3a antigen arises from a nucleotide polymorphism in the choline transporter-like protein-2 gene (SLC44A2), with the resulting variation at amino acid position 154 determining the reactivity of the protein with HNA-3a-specific antibodies; the variant with an arginine at this position, rather than a glutamine, constitutes the HNA-3a antigen. The molecular identification of this antigen should facilitate the development of assays for blood donor screening to lower the risk of TRALI.
Subject(s)
Acute Lung Injury/genetics , Isoantigens/genetics , Membrane Glycoproteins/genetics , Membrane Transport Proteins/genetics , Transfusion Reaction , Acute Lung Injury/immunology , Agglutination Tests , Flow Cytometry , Humans , Isoantigens/immunology , Membrane Glycoproteins/immunology , Membrane Transport Proteins/immunology , Neutrophils/immunology , Phenotype , Polymorphism, Single NucleotideABSTRACT
Septic patients show individually different courses of disease that are hard to predict. Little is known about preconditioning influences that may render one person liable to have overwhelming hyperinflammatory response syndrome (systemic inflammatory response syndrome) and another from compensatory anti-inflammatory response syndrome. Here, we show in a murine model that chronic psychological stress before the onset of polymicrobial peritonitis influences the balance between both types of immune response. Chronically stressed mice which had increased lymphocyte apoptosis, severe functional lymphocyte defects, and an anti-inflammatory cytokine bias had a reduced mortality rate during the continuous outflow of gut content in the hyperinflammatory sepsis model of colon ascendens stent peritonitis. In contrast, they had enhanced long-lasting bacterial dissemination in a sepsis model of mild cecal ligation and puncture. Chronic stress therefore is an important preconditioning factor in the individuals' ability to cope with systemic infections after abdominal surgery. It ameliorates lethal shock responses but reduces the capacity to eradicate bacterial infection during mild peritonitis.
Subject(s)
Peritonitis/pathology , Acoustics , Animals , Apoptosis , Bacteria/metabolism , Colon/pathology , Cytokines/metabolism , Disease Models, Animal , Female , Inflammation , Lipopolysaccharides , Lymphocytes/metabolism , Mice , Mice, Inbred BALB C , SepsisABSTRACT
No data on lipopolysaccharide-binding protein (LBP) in newborns with sepsis have been available up to now. We therefore determined levels of LBP and soluble CD14 (sCD14) in plasma of healthy and septic neonates in order to evaluate their potential diagnostic role. The study included prospectively collected patient samples of two recently published studies on cytokine expression in neonatal sepsis. Twenty-nine septic patients were enrolled in the present analysis. Samples--either cord blood or peripheral blood--from patients admitted within the first 24 h of life for suspicion of sepsis and cord blood samples of a control group of 40 healthy mature infants delivered spontaneously were analyzed. For seven patients of the septic group, a second sample collected between 24 and 48 h of life was available. Levels of sCD14 and LBP in plasma were determined by an enzyme immunoassay using recombinant CD14 and LBP as standards. LBP and sCD14 were correlated to cytokine plasma levels. In septic neonates, LBP (median, 36.6 versus 7.8 microg/ml; P < 0.001) and sCD14 (median, 0.42 versus 0.28 microg/ml; P < 0.001) levels were highly elevated when compared to those of healthy neonates and strongly correlated to granulocyte colony-stimulating factor (G-CSF), interleukin-1beta (IL-1beta), IL-6, and IL-8 levels. LBP levels in septic neonates analyzed between 24 and 48 h of life even increased when compared to samples obtained at or shortly after delivery (median, 36.6 versus 60 microg/ml; P = 0.038). In summary, levels of LBP in plasma of neonates with early-onset sepsis are significantly elevated; the elevated plasma levels seem to persist for more than 24 h, which could provide the clinician with a prolonged time period to identify the newborn with bacterial sepsis.